Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02731807 · ClinicalTrials.gov registry record · Phase 1
TA-65 Pharmacokinetic Study
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02731807 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants.
The verdict
NCT02731807, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is a pilot research study in humans to determine the steady state pharmacokinetic profile of TA-65 after oral dose of formulated and unformulated forms. There will be eight (8) subjects of healthy men and women (non-child bearing). TA-65 is supposed to supplement the diet to increase general health through telomerase activation.The active ingredient in TA-65 activates an enzyme called telomerase. However, the active ingredient has poor oral bioavailability in humans. This study is created to enhance the bioavailability in telomerase with different formulations; powder and capsule form.
Interventions
- DIETARY_SUPPLEMENT Dose A: TA-65 24mg, powder
- DIETARY_SUPPLEMENT Dose B: TA-65, 8mg, powder
- DIETARY_SUPPLEMENT Dose C: TA-65 3.2mg, capsule
- DIETARY_SUPPLEMENT Dose D: TA-65 8mg, capsule
- DIETARY_SUPPLEMENT Dose E: TA-65 32mg, capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02731807
The ClinicalTrials.gov registry entry for NCT02731807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dose A: TA-65 24mg, powder is the first listed.
NCT02731807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02731807 about?
NCT02731807 is a clinical study titled "TA-65 Pharmacokinetic Study". This study is a pilot research study in humans to determine the steady state pharmacokinetic profile of TA-65 after oral dose of formulated and unformulated forms. There will be eight (8) subjects of healthy men and women (non-child bearing). TA-65 is supposed to supplement the diet to increase gene...
What is the current status of trial NCT02731807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-09. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02731807?
The interventions under investigation include: Dose A: TA-65 24mg, powder (DIETARY_SUPPLEMENT), Dose B: TA-65, 8mg, powder (DIETARY_SUPPLEMENT), Dose C: TA-65 3.2mg, capsule (DIETARY_SUPPLEMENT), Dose D: TA-65 8mg, capsule (DIETARY_SUPPLEMENT), Dose E: TA-65 32mg, capsule (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02731807?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.